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ABSTRACT: The aim of this study is to verify if water-
soluble porphyrins can be used as proteasome inhibitors. We
have found that cationic porphyrins inhibit proteasome
peptidase activities much more effectively than the corre-
sponding anionic derivatives. The relevance of electrostatics in
driving porphyin−proteasome interactions has been confirmed
by the observation that the inhibitory efficiency of the cationic
macrocycles decreases with the number of positive sub-
stituents. We have also investigated various metalloporphyrins,
which differ due to the different propension of the central
metal ion toward axial coordination. Our experimental results indicate that the naked cationic porphyrins are the most active in
reversibly inhibiting the three main protease activities of the proteasome in the micromolar range. A spectroscopic
characterization of porphyrin−proteasome interactions by UV−vis spectra parallels the results of inhibition assays: the higher the
inhibitory effect the stronger the spectroscopic variations are. To interpret the action of porphyrins at a molecular level, we have
performed calculations evidencing that cationic porphyrins may hinder the access to the canonical proteolytic site on the
proteasome β5 subunit. In particular, an inspection of the top-scoring docking modes shows that the tetracationic porphyrin
blocks the catalytic pocket, close to the N termini of the β5 proteasome subunit, more efficiently than its anionic counterpart.
Proteasome inhibition activity of porphyrins unites their known anticancer properties making them suitable as a scaffold for the
design of novel multitargeted molecules.
■ INTRODUCTION
Porphyrins are quite unique molecules. Their extended π
system leads to a remarkably high extinction coefficient and
make them highly hydrophobic. Yet, functionalization (mainly
at the meso- positions) with charged substituents makes them
water-soluble; the number and reciprocal dispositions of
charged peripheral groups allows, in turn, to modulate their
tendency to (self-)aggregate.1,2 Porphyrins can be regarded as
polytopic complexing agents because, in addition to the
chemistry related to the periphery (which is tunable in terms
of number, nature, and reciprocal disposition of substituents),
the central core also has a manifold role in determining their
physicochemical behavior.3,4 In fact, besides protonation,
insertion of different metal ions in the four-nitrogen core
gives additional control of the spectroscopic features (especially
concerning the emission properties) and permits us to tune the
interactions of these macrocycles with templates as well as their
self-assembly processes. For example, the presence of one or
two water molecules axially coordinated to the central metal
ions (penta- and hexa-coordinated cationic metalloporphyrins
cannot intercalate but mainly interact with the external
phosphates. Yet, the penta-coordinated ZnT4 is a very sensitive
reporter for the left-handed Z-DNA), strongly influences the
type of interactions with DNA.5,6 All of these peculiar
properties made this class of molecules suitable candidates for
various applications ranging from material science to medicine.7
In oncology, porphyrins find extended application such as
photosensitizers in photodynamic therapy (PDT),8,9 an
approved anticancer procedure in which a photosensitive
molecule, upon exposure to radiation of appropriate wave-
length, induces oxidative damage in tumor cells by means of
singlet oxygen and ROS productions.10 Also, carboranylated
porphyrins have been used as boron carriers in boron neutron
capture therapy (BNCT),11 another anticancer therapy, in
which the bombardment of10B, with thermal neutrons, triggers
a nuclear reaction whose destructive potential covers a range of
a cell diameter.12
In addition to this, it has been recently demonstrated that
some porphyrins, including meso-tetrakis(4-N-methylpyridyl)-
porphine (H2T4), inhibit telomerase an enzyme which, in
adult, is expressed in tumor cells only (the function of
telomerase is correlated to senescence and cell death; in cancer
cells, alterated telomerase activity restores the entire telomeric
sequence after each division of the cell rendering it immortal).
Szokalska and co-workers16 demonstrated that cytotoxic effects
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caused by a porphyrinic photosensitizer in PDT could be
potentiated through inhibition of the proteasome. This finding
encouraged us to investigate the ability of porphyrins to inhibit
the proteasome activity: the central idea is that instead of using
a cocktail of active molecules it would be more convenient to
use one single molecule having different biological targets but
all converging toward the cure of tumors.
The ubiquitin−proteasome system (UPS) is the major
cytosolic proteolytic system in prokaryotes and eukaryotes17
with critical functions in cell cycle control, apoptosis,
inflammation, transcription, signal transduction, protein quality
control, and many other biological processes.18 The end point
of the UPS is the 26S proteasome, an endoprotease of about
2.5 megadaltons that functions primarily to degrade proteins
that have been modified by the attachment of ubiquitin.19 The
26S proteasome is composed of a catalytic core (also known as
the 20S particle) and two 19S regulatory complexes.20 The 19S
caps contain a lid- and baselike structure: the lid component is
responsible for recognizing polyubiquitinated substrates and
deubiquitinating activity, which allows recycling of ubiquitin
moieties. The 20S proteasome is a barrel-like structure whose
subunits are arranged in four stacked seven-membered rings,
each enclosing a central chamber. Seven different but related
α1−α7 subunits form the two outer rings, whereas the two
inner rings are composed of seven different β1−β7 subunits
that contain the proteolytic sites. Each subunit uses the
nucleophilic γ-hydroxy group of the N-terminal Thr to
efficiently hydrolyze peptide bonds. They differ in substrate
specificity: the β1 subunit possesses a postglutamyl peptide
hydrolyzing (PGPH) or caspaselike activity; the β2 subunit has
a trypsinlike (T-L) activity; the β5 subunit possesses a
chymotrypsin-like (ChT-L) activity.21 The proteasome regu-
lates the activity of signal transduction pathways, such as the
NF-κB pathway, degradation of tumor suppressor genes, such
as p53, and oncogenes.22 For these reasons, proteasome
inhibition has become a new, promising strategy in cancer
therapies.23 Several compounds, both natural and synthetic,
have been found to affect UPS functionality,24−26 and some
proteasome inhibitors are already efficient anticancer drugs.
The biggest success so far, in targeting ubiquitin-dependent
processes, has been the development of bortezomib, the first
proteasome inhibitor to be approved for clinical use in human
cancers.27
Synergic cytotoxic effect between proteasome inhibition and
PDT probably arises from the severe oxidative damage of
cellular macromolecules, including proteins that undergo
multiple modifications such as fragmentation, cross-linking,
and carbonylation, caused by photoirradiation of the sensi-
tizers.16 The major mechanism for elimination of carbonylated
proteins is their degradation by proteasome. Therefore,
inhibition of proteasome should result in the accumulation of
molecules leading to fatal (cancer) cell damage.
Inspired by this scenario, we focused our attention on
assessing the ability of porphyrins, highly versatile photo-
sensitizers, to be active as proteasome inhibitors.
■ MATERIALS AND METHODS
Chemicals. The meso-tetrakis(4-N-methylpyridyl) porphyr-
in (H2T4), cis-diphenyl-di-(N-methyl-4-pyridyl)-porphyrin (cis-
T4), monophenyl-tri-(N-methyl-4-pyridyl)-porphyrin (tris-T4),
meso-tetrakis(4-sulphonatophenyl)-porphyrin (H2TPPS) were
purchased from Midcentury, whereas the Mn(II), Zn(II),
Cu(II) derivatives were obtained from metalation of H2T4 as
elsewhere reported.28
Purified rabbit proteasome 20S, fluorogenic substrates Suc-
Leu-Leu-Val-Tyr-AMC, Z-Leu-Leu-Glu-AMC and Ac-Arg-Leu-
Arg-AMC were purchased from Boston Biochem. Dulbecco’s
Minimum Essential Medium (DMEM), penicillin streptomycin,
fetal calf serum were purchased from Invitrogen.
Preparation of Cell Lysates. To obtain cell lysates for
proteasome activity assays, HeLa cells were grown in DMEM
supplemented with Fetal Calf Serum 10% and were mantained
at 37 °C in a humidified 5% CO2 incubator. Whole cell lysates
were prepared by freeze−thawing cycles in water containing 1
mM dithiothreitol (DTT).29 The lysate was then centrifuged at
14,000 rpm for 30 min and the supernatant brought to 50 mM
Hepes (pH 7.5) containing 5 mM MgCl2 and 250 mM sucrose
and 1 mM DTT (buffer A). We quantified the protein content
of lysates using the Bradford method, (protein assay kit,
BioRad), and then incubated equal amounts of protein with the
indicated amounts of inhibitor, substrate, and buffer for 30 min
at 37 °C.
20S, 26S Proteasome Activity. We have selected three
specific fluorogenic peptides conjugated with the fluorophore
amido-4-methyl coumarin (AMC). In particular, Suc-LLVY-7-
amido-4-methyl coumarin, Z-Leu-LeuGlu-AMC, and Ac-Arg-
Leu-Arg-AMC were used to test the ChT-L, PGPH-L, and T-L
activity, respectively. Proteasome activity is monitored by
measuring AMC fluorescence at 440 nm (infra). In the absence
of proteasome activity, fluorescence is almost negligible and
does not change with time. On the contrary, in the presence of
some cleaving activity AMC emission at 440 nm increases with
time and the slope of the emission versus time plot is correlated
to proteasome activity. For the sake of a more intuitive
approach, data are expressed as percentages of residual activity
considering the slope of the control (peptide−AMC/
proteasome in the absence of inhibitors) as 100% (Figure S1
of the Supporting Information). To rule out any misinter-
pretation of the inhibition assays due to a possible overlap of
porphyrin and AMC fluorescence emissions, we have
preliminarly collected spectra of AMC/porphyrins mixtures in
the same experimental conditions adopted hereafter and found
no interference.
Cell lysates (4 μg in proteins) or purified rabbit 20S
proteasome (2 nM) were previously incubated in the presence
of porphyrin in 200 μL buffer for 30 min at 37 °C. In particular,
we used buffer A supplemented with 30 μM ATP for 26S
proteasome activity and the reaction buffer (Hepes 20 mM, 0.5
mM EDTA) for 20S activity. In some 20S activity assays, the
buffer was also supplemented with 0.03% SDS.29
In all assays, the reaction started with fluorogenic substrates
addition (100 μM) and the AMC release was followed
measuring fluorescence emission at 440 nm (excitation at 360
nm) for 20 min using a fluorescence plate reader (Varian Cary
Eclipse). Concentration−response plots of the residual activity
of the proteasome in the presence of the inhibitor may provide
a quantitative estimate of its potency. The IC50 (i.e., the
concentration of the inhibitor which causes the 50% reduction
of activity) is identified from the midpoint of the concentration
−response plot occurring at a fractional activity of 50% and
corresponding to 50% inhibition of proteasome. The
reversibility of inhibition was determined by measuring the
recovery of enzymatic activity after a rapid and greater dilution
of the proteasome porphyrin complex as previously reported.30
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UV−vis and Fluorescence Spectra. UV−vis spectra were
recorded by a JASCO V-530 spectrophotometer and
fluorescence spectra were measured by Cary Eclypse Varian
and by FL3 Jobin Yvon Horiba spectrofluorimeter. UV−vis
spectra of porphyrin solutions in presence of 20S proteasome
were performed in reaction buffer in the absence of SDS.
Hypochromicity is calculated by subtracting the absorbance of
the Soret band of the sample porphyrin/proteasome from the
absorbance of the sample containing porphyrin alone.
Molecular Modeling. Cationic and anionic porphyrins
were docked to the 20S proteasome cocrystallized with
bortezomib (PDB code: 2F16) by using AutoDock Vina.31,32
The binding site was defined as an area with a diameter of 40 Å
around the coordinates of the mass center of bortezomib in
PDB 2F16. Before docking calculations, ligands were removed
and hydrogen atoms added to the β5 subunit of the 20S
proteasome. Protein structure was kept fixed during docking
simulations. Water was implicitely considered throughout all
calculations assuming a dielectric constant of the medium of 80.
All rotatable torsion angles of the porphyrin were allowed to
rotate freely, and the 10 lowest energy structures were stored
for further analysis. A total of 100 docking runs were computed
for each ligand. Input files for the planar ligands were obtained
from the Dundee PRODRG2 server. Nonplanar porphyrins
were obtained by semiempirical geometry optimization using
the AM1 methods in the Hyperchem software package.33 The
options selected for the optimization runs were: convergence
limit 0.01, iteration limit 50, total charge 0, state lowest,
minimization algorithm Polak-Ribiere.
■ RESULTS AND DISCUSSION
Screening the Proteasome Inhibition Ability of
Porphyrins in 20S Proteasome Preparations from Cell
Lysates. The list of compounds that affect proteasome activity
is already lengthy and several attempts have been made to
summarize the actual knowledge about the most effective
among these molecules.34 Unfortunately, because of differences
in the experimental conditions employed (e.g., buffer,
proteasome source, methods) the values of the inhibiting
potential, reported in different works for the same inhibitor, can
vary significantly, thus making a safe comparison difficult. In an
attempt to (partially) circumvent this drawback, we decided to
quantify the proteolytic activity of the proteasome in the
preparations identified as 20S cell lysates. Indeed, cell lysates
are largely employed in studies aimed at probing the capability
of many proteasome inhibitors and are, then, expected to
provide the largest array of comparable data available in the
literature to date.29 Therefore, the capacity of different
porphyrin derivatives to inhibit the ChT-L activity of 20S
proteasome in cell lysates was first assayed.
Owing to the lack of studies concerning the activity of
porphyrins as proteasome inhibitors, we started our studies
with a quite crude screen involving only the tetracationic H2T4
and the tetraanionic H2TPPS. This initial experiment
(performed at 1 μM of porphyrins) already gives a very clear
indication: H2T4 quenches ChT-L proteolitic activity but
H2TPPS does not. Figure 1 shows that the plot of the slope of
the emission (related to proteasome activity) versus time −
measured in the presence of the tetraanionic porphyrins − is
almost identical to that shown by proteasome alone (90% vs
100%), whereas the presence of the tetracationic porphyrin
H2T4 causes quite a drastic reduction of the slope (65% of
reduction) indicating a remarkable inhibition activity of this
macrocycle. These coarse data give a first clear indication
suggesting that electrostatics play a very important role in
regulating porphyrin−proteasome interactions.
To focus better on this aspect, we performed proteasome
activity assays using porphyrins with three or two cationic
substituents, respectively (Chart 1). The outcome of these
experiments (Figure 2) is perfectly in line with the expectations
coming from the previous experiment. This shows that
Figure 1. Residual chymotryptic-like activity of 20S proteasome in cell
lysates in presence of H2TPPS and H2T4 at 1 μM. Data are referred to
control sample normalized to 100%.
Chart 1. Chemical Structures of All the Porphyrin
Derivatives Used in This Study
Figure 2. Residual chymotryptic-like activity of 20S proteasome in cell
lysates with di-, tri- and tetracationic porphyrins at 1 μM. Data are
referred to control sample normalized to 100%.
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proteasome inhibition decreases linearly with the number of
positive charges (the inhibiting ability of the dicationic
porphyrin is indeed comparable to that shown from the
tetraanionic derivative) substantiating the key role of the
electrostatics in tuning proteasome−porphyrin interactions.
As mentioned before, porphyrins can be considered
polytopic complexing molecules with quite a defined center
and a tunable periphery. Therefore, once assessed the relevance
of the peripheral charge, we thought that investigating the
influence of the central metal ion on the inhibition activity
would be useful. In fact, as previously discussed, the type and
extent of porphyrin interactions with surrounding molecules are
deeply influenced from the presence of central metal ions that
axially coordinate water molecule(s). Quite notably, it turns out
that the inhibitory efficiency of metalloporphyirns depends on
the coordination properties of the central metal ion (Figure 3).
In particular, a regular increase of inhibition of proteasome
activity is observed going from hexa-(MnT4) to penta-
coordinated (ZnT4) to planar (CuT4) porphyrins suggesting
that axially coordinated water molecules get in the way of
porphyrin−proteasome interactions.
To fully understand the system, we have performed
inhibition measurements also with various metalloderivatives
of the tetra-anionic porphyrin: consistently with the data
previously discussed also the anionic metalloderivatives do not
inhibit protasome activity (data not shown).
To assess whether the spectroscopic features of porphyrins
were modified upon proteasome binding, we performed UV−
vis measurements of the cationic (H2T4) and anionic
(H2TPPS) porphyrins in similar experimental conditions,
(buffer, porphyrin, and proteasome concentrations) adopted
for the activity assay. In this case, to rule out any possible
interaction with nonproteasomal components, only purified
proteasome 20S samples were utilized. UV−vis spectra (left
panel of Figure 4) show that addition of 20S to a solution of the
tetraanionic H2TPPS does not induce any change. On the
contrary, titration of H2T4 with purified proteasome 20S
induces a dose-dependent hypochromic effect of the Soret band
of H2T4 (right panel of Figure 4 and the insert). Noticeably
these changes are stable over 24 h.
Hypochromic effect is observed for all metalloderivatives of
the cationic porphyrins. Intriguingly, the trend of the
proteasome inhibition activity observed for the different
porphyrins tested, both in terms of charges and role of the
central metal, is paralleled by the UV−vis binding measure-
ments (Figure 5). The degree of hypocromicity, in fact,
correlates with the inhibitory activity of the various porphyrins
and, as shown in Figure 5, in turn depends on the coordination
features of the central metal.
The UV−vis variations observed in these experiments
exclude porphyrins aggregation. Porphyrin aggregation leads,
in fact, to broadening of the Soret band accompanied from
noticeable hypochromicity: comparison of the spectrum of the
free and proteasome bound H2T4 does not show any of these
signs. Moreover, Resonance Light Scattering (RLS) of
proteasome-bound H2T4 (Figure S2 of the Supporting
Information) ruled out, definitively, the presence of aggregated
species.
Proteasome Activity Assays in Cell Lysates and
Purified 20S Proteasome Preparations. All of the assays
described above were performed adopting the experimental
conditions most frequently used in studies in which proteasome
activity in crude biological samples was measured. However,
because nonproteasomal peptidases (e.g., cathepsins) could
also hydrolyze the fluorogenic peptides under these exper-
imental conditions, these assays are expected to be nonspecific
and variations in fluorescence emission may be difficult to be
rationalized in terms of proteasomal activity alone. Examples of
such questionable interpretations have already been reported
Figure 3. Residual chymotryptic-like activity of 20S proteasome in cell
lysates with different metalated porphyrins (MnT4, ZnT4, and CuT4)
at 1 μM. Data are referred to control sample normalized to 100%.
Figure 4. UV−vis spectra of H2TPPS (left panel) at 4 μM (path
length 0.1 cm) in reaction buffer in absence (solid line) and in
presence of purified proteasome 20S (open circles). Right panel: UV−
vis titration of 4 μM H2T4 (path length 1 cm) with increasing
amounts of 20S proteasome. The insert reports a plot of the
hypochromic effect vs proteasome concentration.
Figure 5. Black line, hypochromic effect of Soret band in UV−vis
spectra of different porphyrins at 4 μM following addition of 2 nM 20S
proteasome (square points, left Y axis); blue line, percentage of
residual ChT-L activities of 20S proteasome (circle points, right Y
axis).
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and include the significant variations in proteasomal activity of
the cytosolic fractions of homogenized tissues, which were
assessed by fluorogenic substrates.35,36 Consequently, only a
comparison of the activity assays performed in cell lysates and
in isolated 20S proteasome preparations may account for the
specificity of the inhibitor. To address this point, the inhibitory
efficiency of all porphyrins studied in this work has been tested,
in a concentration range going from 0.5 to 3 μM, against
purified 20S (the dose−response curves are shown in Figure S3
of the Supporting Information). Also, these experiments
underline the major activity of H2T4 with respect to all the
other porphyrins. For this reason, in the following part of the
manuscript we will discuss only the data concerning the activity
of H2T4 that was assayed (always in a concentration range 0.5
to 3 μM) by probing the ChT-L activity either in purified
proteasome samples and in cell lysates (Figure 6).
The peptidease activity of purified 20S proteasome and of
cell lysates are inhibited by porphyrins to a similar extent; the
small differences observed can then be ascribed to the presence
of nonproteasomal peptidases in crude biological samples. In
fact, previous studies have demonstrated that immunoprecipi-
tation of the proteasome from crude biological samples resulted
in 70−80% reduction in ChT-L activity.37 This means that the
residual peptidase activity (20−30%) may be ascribed to
nonproteasomal peptidases that may not be inhibited by
specific proteasome inhibitors.
Although literature data may significantly vary depending on
the biological source, the kind of assay employed and the
concentration of inhibitor used, our data are in line with those
indications and suggest that H2T4 is a quite specific proteasome
inhibitor.
A comparative study of the 26S proteasome activity (black
squares in Figure 6) has also been performed in the presence of
H2T4 and in the same experimental conditions previously
adopted for the 20S assay. The lower inhibitory potency
exerted by H2T4 for these proteasome preparations may be,
thus, related to the presence of the regulatory lids that may
(slightly) hinder the entrance of the inhibitor in the catalytic
chamber. Yet, the similar inhibition effect found for H2T4 with
20S and 26S substantiates the hypothesis that the mechanism
of inhibition foresees porphyrin interaction with the catalytic
core of the proteasome.
The ChT-L activity of the proteasome is mostly probed to
evaluate proteasomal activity in crude biological samples, or in
the isolated proteasome, due to previous reports suggesting that
the chymotryptic substrate is the most proteasome-specific of
those examined.29 Nevertheless, the three activities of the
proteasome are allosterically regulated38 and measuring only
chymotriptic-like activity may not fully account for total
proteasome activity. To address this issue, we decided to
probe all the three proteolytic activities of the proteasome.
Quantifying the Inhibiting Potential of H2T4. Figure 7
illustrates the concentration−response plots for the inhibition
of the three 20S proteasome activities in the presence of H2T4.
The insert of Figure 7 reports the IC50 values of the inhibitor.
To understand the mechanism of interaction betweeen
porphyrins and proteasome active sites, we checked for the
reversibility of H2T4-mediated proteasome inhibition on
chymotryptic-like activity. A convenient method for determin-
ing reversibility consists in incubating proteasome solution at
100-fold concentration (2 × 10−7 M) over that required for the
activity assay (2× 10−9 M), with H2T4 solution at
concentration equivalent to 10-fold the IC50 (1× 10
−5 M).30
After 30 min, this mixture was diluted 100-fold into reaction
buffer containing the substrate of chymotryptic-like activity to
start the reaction; the activity was then measured and compared
to that of a similar sample of proteasome incubated and diluted
in the absence of H2T4 porphyrin. Proteasome chymotryptic-
like activity is fully recovered after dilution showing fast
reversibility of binding between H2T4 and proteasome active
binding site.
Molecular Modeling of the Proteasome−Porphyrin
Complex. On the basis of the evidence that cationic porphyrin
inhibits the proteolytic active site on the proteasome β5
subunit, which is also the target of lactacystin and
Bortezomib,39,40 we set out to generate a tentative model of
the porphyrin/proteasome complex by molecular modeling.
Indeed, because the different proteasome proteolytic sites have
a common, evolutionary origin (and cationic porphyrins inhibit
all catalytic functions comparably well), we expect a common
mode of binding to all three pockets as already observed for
other proteasome inhibitors.41 The first binding mode of planar
porphyrins for the β5 subunit is very similar to the following
two lower-affinity poses, therefore, we propose them to be
Figure 6. Concentration−response plot of H2T4 for chymotryptic-like
activity on 26S and 20S (either from cell lysates or purified 20S
proteasome).
Figure 7. Concentration−response plot of H2T4 for chymotryptic-
like, caspaselike, and trypticlike residual activies on 20S from cell
lysates.
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representative of the porphyrin/proteasome complexes. How-
ever, although planar structures of H2T4 have been inferred
from X-rays diffractions studies42 nonplanar distortions are
largely documented. So, we carried out docking simulations
using also saddlelike conformations obtained by semiempirical
optimization runs. We note that saddlelike conformations of
H2T4 may hinder the access to the active site (bottom left part
of Figure 8). Notably, parallel docking calculations, performed
with the inactive anionic porphyrin H2TPPS, never evidenced
binding poses close to the N-termini of the β5 subunit (as
reported in the bottom right of Figure 8). Although we are
aware that it may be unwise to overemphasize the outcome of
docking runs, we have to remark that they reconcile with the
results of inhibition studies.
■ CONCLUSIONS
Over the past decade, it has been increasingly recognized that
cancer is a complex disease that is caused by multiple genetic
and environmental factors. It is thus quite conceivable that the
traditional reductionist model one drug−one target may not
hold in this case opening the way to new drugs that address
multiple targets.43 Inspired by these scenarios, and, bearing in
mind that photosensitizers are already used in many cancer
treatments, we have screened a number of porphyrin derivatives
to assess their efficiency as proteasome inhibitors. Among all
porphyrins, cationic derivatives have attracted particular
attention since they interact with anionic phosphate groups
of DNA thus causing additional cell damage upon irradi-
ation.44−47 Furthermore, cationic porphyrins are known to
interact with the negatively charged lipid membranes of the cell,
facilitating their diffusion across the lipid bilayer and thus
enhancing their efficacy.48 Our experiments demonstrate that
tetracationic porphyrins, and some of its metallo derivatives,
may significantly inhibit all the three catalytic functions of the
20S and the 26S proteasome either in crude biological samples
or in isolated 20S proteasome preparations. The most active
compound, H2T4, has a similar inhibitory ability for all the
three catalytic sites and comparable with other inhibitors such
as lactacystin (IC50 in the micromolar range) although with a
faster off-rate from the proteasome. Notably, reversible
proteasome inhibitors have been proposed to result in better
antitumor activity by exhibiting a better tolerability in affected
tissues.49,50 Therefore, on the basis of molecular modeling we
probed the binding mode of H2T4 to the active site of the β5
subunit. The low toxicity of porphyrins and their effective
proteasome inhibition encourage us to continue our evaluation
of this class of compounds.
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